4.2 Article

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis

Journal

ARTHRITIS RESEARCH & THERAPY
Volume 19, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13075-017-1289-x

Keywords

Rheumatoid arthritis; Disease activity; Prediction; Markov model; Clinical Disease Activity Index

Categories

Funding

  1. Corrona, LLC
  2. AbbVie Inc.
  3. Amgen Inc.
  4. Astra Zeneca
  5. Bristol-Myers Squibb Co.
  6. Crescendo Pharmaceuticals Corp.
  7. Genentech Inc.
  8. Horizon Pharma USA
  9. Janssen Pharmaceuticals, Inc.
  10. Eli Lilly and Co.
  11. Novartis International AG
  12. Pfizer Inc.
  13. UCB, Inc.
  14. Immunex
  15. Wyeth

Ask authors/readers for more resources

Background: We examined models to predict disease activity transitions from moderate to low or severe and associated factors in patients with rheumatoid arthritis (RA). Methods: Data from RA patients enrolled in the Corrona registry (October 2001 to August 2014) were analyzed. Clinical Disease Activity Index (CDAI) definitions were used for low (<= 10), moderate (> 10 and <= 22), and severe (> 22) disease activity states. A Markov model for repeated measures allowing for covariate dependence was used to model transitions between three (low, moderate, severe) states and estimate population transition probabilities. Mean sojourn times were calculated to compare length of time in particular states. Logistic regression models were used to examine impacts of covariates (time between visits, chronological year, disease duration, age) on disease states. Results: Data from 29,853 patients (251,375 visits) and a sub-cohort of 9812 patients (46,534 visits) with regular visits (every 3-9 months) were analyzed. The probability of moving from moderate to low or severe disease by next visit was 47% and 18%, respectively. Patients stayed in moderate disease for mean 4.25 months (95% confidence interval: 4.18-4.32). Transition probabilities showed 20% of patients with low disease activity moved to moderate or severe disease within 6 months; >35% of patients with moderate disease remained in moderate disease after 6 months. Results were similar for the regular-visit sub-cohort. Significant interactions with prior disease state were seen with chronological year and disease duration. Conclusion: A substantial proportion of patients remain in moderate disease, emphasizing the need for treat-to-target strategies for RA patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available